Annexon (ANNX) Other Non-Current Liabilities (2020)
Annexon's (ANNX) quarterly Other Non-Current Liabilities came in at $10.8 million in Q4 2020, little changed quarter-over-quarter from $10.8 million in Q3 2020.
Annexon (ANNX) Other Non-Current Liabilities (2020) Analysis & Trends
Annexon's Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $10.8 million for Q4 2020.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $10.8 million in Q4 2020; TTM through Dec 2020 was $10.8 million, a N/A change from a year earlier, with the FY2020 full-year figure at $10.8 million, changed N/A from the prior year.
- Other Non-Current Liabilities held at $10.8 million in Q4 2020 per ANNX's latest filing, from $10.8 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $10.8 million in Q3 2020 and bottomed at $10.8 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Annexon | 1.03 Bn | 804.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 10.80 Mn |
| Sep 30, 2020 | 10.80 Mn |